Galderma stock faces CFO transition ahead of December EGM

Published on 11/03/2026 at 12:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Galderma stock faces a planned CFO departure and proposed board changes. Shareholders will vote on the appointments at an extraordinary meeting in December.

Governance changes set for vote

Luigi La Corte will leave Galderma after a transition period, with succession details still to come.
Shareholders will consider two proposed board appointments and a larger board at the extraordinary meeting.

Galderma, CH1335392721, Illustration mit AI erstellt.

Galderma announced a planned Chief Financial Officer transition and proposed board changes on Monday, November 2, 2026. In a Galderma press release, the dermatology group said Luigi La Corte will leave the company to pursue a new opportunity.

La Corte will remain CFO during the transition to support business continuity and a smooth handover. Galderma said it will provide further details on the succession arrangements and transition timeline in due course.

Board proposals go to shareholders

The Board has nominated Rosalind Brewer and Petra Rumpf as new directors. The company said the candidates bring experience across consumer businesses, healthcare, medtech and life sciences.

The proposals will be put to an extraordinary general meeting on December 3, 2026, held virtually at 14:00 CET. The agenda also calls for the maximum Board size to rise from 10 to 11 members. Brewer and Rumpf would serve until the close of the next Annual General Meeting if elected.

Sherilyn McCoy is set to leave the Board after seven years because of conflicting obligations. Galderma is also proposing Brewer for individual election to the Compensation Committee. The measures are intended to reinforce governance as the company develops its Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology businesses.

Stock context for investors

Galderma stock traded at 205.00 euros on Lang & Schwarz at 12:01 CET on Tuesday, November 3, 2026. Investors now have two company-specific issues to follow: the CFO succession process and the shareholder vote on the proposed Board structure.

The company has not yet named a successor or given a detailed timetable for the CFO handover. That leaves the December meeting and subsequent succession update as the next identifiable governance milestones. The real-time quote of Galderma stock provides the latest trading reference.